MeSH D018805 - sepsis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D018805:Â
Sepsis
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Ceftriaxone | Ceftriaxone |  | 2007-03-15 |  |  |
| GSK | Ceftazidime | Ceptaz |  | 1990-09-27 |  |  |
| Ceftazidime | Pentacef |  | 1995-11-07 |  |  | |
| Roche | Ceftriaxone, Lidocaine | Rocephin |  | 1985-03-12 | $261.442 M | Y2021 |
| Lupin Research | Cefotaxime | Cefotaxime |  | 2003-09-24 |  |  |
| Ceftriaxone | Ceftriaxone |  | 2003-09-30 |  |  | |
| Sandoz | Ceftriaxone | Ceftriaxone |  | 2005-05-17 |  |  |
| Sanofi | Cefotaxime | Claforan |  | 1987-01-13 |  |  |
| Allergan | Avibactam, Ceftazidime | Avycaz | 2026-01-07 | 2015-02-25 | $98.8 M | Q2/19-Q1/20 |
| Pfizer | Avibactam, Ceftazidime | Zavicefta |  | 2016-06-23 | $511 M | Y2023 |
| Eli Lilly | Ceftazidime | Tazidime |  | 1985-11-20 |  |  |
| Drotrecogin alfa (activated), Drotrecogin alfa | Xigris |  | 2002-08-22 |  |  | |
| Aurobindo Pharma | Cefotaxime | Cefotaxime |  | 2009-11-06 |  |  |
| Ceftazidime | Ceftazidime |  | 2010-05-28 |  |  | |
| Ceftriaxone | Ceftriaxone |  | 2008-07-31 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
86%31/36
Phase 2
75%54/72
Phase 3
40%41/103
Approved: 5Overall Success rate: 26%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use